



INTERNATIONAL GENERIC AND  
BIOSIMILAR MEDICINES ASSOCIATION

## PRESS RELEASE

1 February 2018

Contact: David Gaugh [igba@igbamedicines.org](mailto:igba@igbamedicines.org)

## IGBA LAUNCHES A BIOSIMILAR MEDICINES INFORMATION CAMPAIGN

Today, the International Generic and Biosimilar medicines Association (IGBA) launched an information campaign on biosimilar medicines. The foundation of this campaign is the IGBA biosimilar medicines public slide deck<sup>1</sup>. Access to well-referenced information is fundamental to improving worldwide understanding and acceptance of biosimilar medicines, which support patient access to life-saving treatments, enhance competition and contribute to healthcare system sustainability by offering savings for the same medical outcome.

Biosimilar medicines, like their reference medicinal products, help treat many complex diseases, including cancers, rheumatoid arthritis, psoriasis, inflammatory bowel disease, growth disorders and diabetes.

The EU has approved the highest number of biosimilar medicines worldwide, and has acquired considerable experience of their use and safety. There is real world experience available of over 700 Million patient days from EU licensed biosimilar medicines alone<sup>2</sup>, and *“over the last 10 years, the EU monitoring system for safety concerns has not identified any difference in the nature, severity or frequency of adverse effects between biosimilars and their reference medicine”*<sup>3</sup>. IGBA believes that this accumulated wealth of clinical experience with biosimilar medicines can become a worldwide game-changer for access to medicines for certain complex medical conditions.

The slide deck has been developed to be shared for educational purposes with any stakeholder, and is complementary to the extensive information on biosimilar medicines, which has already been made available for example in the USA<sup>4</sup> and the European Union<sup>5</sup>.

<sup>1</sup> [IGBA Communication on biosimilar medicines](#)

<sup>2</sup> [Biosimilar Medicines Clinical Use: An Experience Based-EU Perspective](#)

<sup>3</sup> [EMA – European Commission: Biosimilars in the EU – Information guide for healthcare professionals, 2017 \(link\)](#)

<sup>4</sup> [U.S. FDA Patient and Prescribers Outreach Materials on Biosimilars](#)



**Association for Accessible Medicines**  
601 New Jersey Ave  
NW, Suite 850  
Washington DC 20001  
T: +1 202 249 7100  
[accessiblemeds.org](http://accessiblemeds.org)



**Canadian Generic Pharmaceutical Association**  
4120 Yonge Street  
Suite 409  
Toronto, Ontario  
M2P 2B8, Canada  
T: +1 416 223 2333  
[canadiangenerics.ca](http://canadiangenerics.ca)



**Generic & Biosimilar Medicines Southern Africa**  
1342 Howick Mews,  
Waterfall Park,  
Bekker Rd, Midrand  
Box 32361, Kyalami, 1684  
T: +27 11 312 6966  
[gbmsa.org](http://gbmsa.org)



**Indian Pharmaceutical Alliance**  
A-205 Sangam,  
14B S V Road,  
Santacruz West,  
Mumbai 400054.  
T: +91-22-2610 9281  
[ipa-india.org](http://ipa-india.org)



**Jordanian Association of Pharmaceutical Manufacturers**  
Khalda, Villa No. 1  
Yazan Aranki St.  
P.O. Box 5382  
Amman, 11953 Jordan  
T: +962 6 5413114  
[japm.com](http://japm.com)



**Japan Generic Medicines Association**  
3-3-4 Nihonbashi-honcho  
Chuo-ku, Tokyo  
103-0023 Japan  
T: +81 3 3279 1890  
[jga.gr.jp](http://jga.gr.jp)



**Medicines for Europe**  
Rue d'Arlon 50  
B-1000 Brussels,  
Belgium  
T: +32 2 736 84 11  
[medicinesforeurope.com](http://medicinesforeurope.com)



**Taiwan Generic Pharmaceutical Association**  
Fl. 5, No. 32-1,  
Songjiang Rd.,  
Taipei City 104,  
Taiwan  
T: +886 02-25314389  
[tgpa.org.tw](http://tgpa.org.tw)



**Mexican Association of Generic Medicines**  
Viaducto Miguel Alemán  
No. 193-2  
Col. Escandón  
C.P. 11800 - México,  
D.F.  
T: +52 5273-7708  
[amegi.com.mx](http://amegi.com.mx)



**Generic and Biosimilar Medicines Association**  
PO Box 87  
Deakin West ACT 2600  
[gbma.com.au](http://gbma.com.au)



**Malaysian Organisation of Pharmaceutical Industries**  
Global Business &  
Convention Centre  
Mezzanine floor, block a,  
No. 8, Jalan 19/1, section  
19, 46300 Petaling Jaya  
Selangor Darul Ehsan –  
Malaysia  
T: +603-7931 9003  
[mopi.org.my](http://mopi.org.my)



**Brazilian Generic Medicine Drugmakers Association**  
Rua Alvorada, 1280  
CEP : 04550-004  
São Paulo – SP  
T: +55 (11) 3897-9767  
[progenericos.org.br](http://progenericos.org.br)



## **About IGBA**

The International Generic and Biosimilar Medicines Association (IGBA) was founded as IGPA (International Generic Pharmaceutical Alliance) in March 1997 to strengthen cooperation between associations representing manufacturers of generic medicines from around the world. Its membership includes AAM (USA), CGPA (Canada), GBM – Southern Africa (South Africa), IPA (India), JAPM (Jordan), JGA (Japan), Medicines for Europe (Europe), and TGPA (Taiwan), while the associations from Australia (GBMA), Brazil (ProGenericos), Mexico (AMEGI), and Malaysia (MOPI) are Associate Members. The IGBA is at the forefront of preserving sustainable competition within our industry, by stimulating competitiveness and innovation in the pharmaceutical sector; thereby, ensuring millions of patients around the world have access to high quality, pro-competitive medicines. Through its constituent member associations, the IGBA maintains constant dialogue with government authorities around the world, as well as with international institutions such as WTO, WIPO and WHO. More information: [www.igbamedicines.org](http://www.igbamedicines.org)